...
首页> 外文期刊>Radiation Oncology Journal >Postoperative Radiation Therapy for Chest Wall Invading pT3N0 Non-small Cell Lung Cancer: Elective Lymphatic Irradiation May Not Be Necessary
【24h】

Postoperative Radiation Therapy for Chest Wall Invading pT3N0 Non-small Cell Lung Cancer: Elective Lymphatic Irradiation May Not Be Necessary

机译:侵袭胸壁侵袭性pT3N0非小细胞肺癌的术后放射治疗:选择性淋巴照射可能不是必需的

获取原文

摘要

PURPOSE: No general consensus has been reached regarding the necessity of postoperative radiation therapy (PORT) and the optimal techniques of its application for patients with chest wall invasion (pT3cw) and node negative (N0) non-small cell lung cancer (NSCLC). We retrospectively analyzed the pT3cwN0 NSCLC patients who received PORT because of presumed inadequate resection margin on surgical findings. MATERIALS AND METHODS: From Aug. 1994 till June 2000, 21 pT3cwN0 NSCLC patients received PORT at Samsung Medical Center; all of whom underwent curative en-bloc resection of the primary tumor plus the chest wall and regional lymph node dissection. PORT was typically started 3 to 4 weeks after operation using 6 or 10 MV X-rays from a linear accelerator. The radiation target volume was confined to the tumor bed plus the immediate adjacent tissue, and no regional lymphatics were included. The planned radiation dose was 54 Gy by conventional fractionation schedule. The survival rates were calculated and the failure patterns analyzed. RESULTS: Overall survival, disease-free survival, loco-regional recurrence-free survival, and distant metastases-free survival rates at 5 years were 38.8%, 45.5%, 90.2%, and 48.1%, respectively. Eleven patients experienced treatment failure: six with distant metastases, three with intra-thoracic failures, and two with combined distant and intra-thoracic failures. Among the five patients with intra-thoracic failures, two had pleural seeding, two had in-field local failures, and only one had regional lymphatic failure in the mediastinum. No patients suffered from acute and late radiation side effects of RTOG grade 3 or higher. CONCLUSION: The strategy of adding PORT to surgery to improve the probability, not only of local control but also of survival, was justified, considering that local control was the most important component in the successful treatment of pT3cw NSCLC patients, especially when the resection margin was not adequate. The incidence and the severity of the acute and late side effects of PORT were markedly reduced, which contributed to improving the patients' quality of life both during and after PORT, without increasing the risk of regional failures by eliminating the regional lymphatics from the radiation target volume.
机译:目的:关于术后放疗(PORT)的必要性及其对胸壁浸润(pT3cw)和淋巴结阴性(N0)非小细胞肺癌(NSCLC)患者的最佳应用技术尚未达成共识。我们回顾性分析了由于手术发现的切除余量不足而接受PORT的pT3cwN0 NSCLC患者。材料与方法:1994年8月至2000年6月,共有21例pT3cwN0 NSCLC患者在三星医疗中心接受PORT治疗。所有患者均接受了根治性全切除术,包括原发肿瘤,胸壁和区域淋巴结清扫术。 PORT通常在术后3至4周开始,使用来自线性加速器的6或10 MV X射线开始。辐射目标体积限于肿瘤床加上紧邻的组织,并且不包括区域淋巴管。按照常规分馏方案,计划的辐射剂量为54 Gy。计算存活率并分析失效模式。结果:5年总生存率,无病生存率,无局部区域复发生存率和远处无转移生存率分别为38.8%,45.5%,90.2%和48.1%。 11例患者经历了治疗失败:6例发生远处转移,3例发生胸腔内衰竭,2例合并远处和胸腔内合并衰竭。在5例胸内衰竭患者中,2例行胸膜播种,2例在野外局部衰竭,仅1例在纵隔出现局部淋巴衰竭。没有患者遭受RTOG 3级或更高的急性和晚期放射副作用。结论:考虑到局部控制是成功治疗pT3cw NSCLC患者最重要的因素,尤其是在切除切缘时,在手术中增加PORT来提高局部控制和生存率的策略是合理的。还不够。 PORT的急性和晚期副作用的发生率和严重程度显着降低,这有助于在PORT期间和之后改善患者的生活质量,而不会通过从辐射目标中消除区域淋巴管而增加区域衰竭的风险卷。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号